Loading clinical trials...
Loading clinical trials...
An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Conditions
Interventions
Enfortumab vedotin
Pembrolizumab
+3 more
Locations
260
United States
Ironwood Cancer & Research Centers - Chandler
Chandler, Arizona, United States
Arizona Oncology Associates PD - HOPE
Tucson, Arizona, United States
Providence St Joseph Medical Center
Burbank, California, United States
City of Hope National Medical Center
Duarte, California, United States
University of California Los Angeles Medical Center
Los Angeles, California, United States
University of California Irvine - Newport
Orange, California, United States
Start Date
March 30, 2020
Primary Completion Date
August 8, 2023
Completion Date
March 1, 2028
Last Updated
June 13, 2025
NCT05489211
NCT07259226
NCT06820255
NCT05438537
NCT04044859
NCT04180371
Lead Sponsor
Astellas Pharma Global Development, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions